XLO - NASDAQ
Xilio Therapeutics, Inc.
$8.46
-0.71%Xilio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies to improve the immune system of cancer patients. Its checkpoint inhibitor program includes XTX101, a clinical-stage, tumor-selective anti-CTLA-4 mAb that is in Phase 1/2 clinical trials in patients with solid tumors. The company also develops cytokine programs, which comprises XTX202, a modified form of IL-2; XTX301, an IL-12 product candidate; and XTX401, an IL-15 product candidate that are masked with a protein domain to prevent binding activity until cleaved off by tumor microenvironment (TME)-associated proteases. Xilio Therapeutics, Inc. was founded in 2016 and is headquartered in Waltham, Massachusetts.
At a Glance
Live SnapshotXilio Therapeutics, Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Weak cash conversion. Significant portion of earnings not converting to cash—review working capital trends and capital intensity.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Strong FCF growth demonstrates improving cash generation and business momentum. Positive signal for sustainability.
Working Capital Impact
Working capital inflow boosted cash flow. Efficient management of receivables, inventory, and payables contributing positively.
Xilio Therapeutics, Inc. Cash Flow Statement
XLO • NASDAQ
| Xilio Therapeutics, Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | |||||||
-35M | -58.2M | -76.4M | -88.2M | -75.8M | -55.2M | -17.3M | |
1.5M | 1.6M | 1.9M | 1.8M | 1.5M | 1.1M | 240K | |
0.0 | 0.0 | 0.0 | 0.0 | 222K | 0.0 | -1.7M | |
6.9M | 6.4M | 7.4M | 8.4M | 5M | 1.3M | 112K | |
-3.6M | 3K | 160K | 224K | 173K | 165K | 56K | |
25.1M | 31.8M | -1.7M | 2M | -11.8M | 16.6M | 797K | |
-5M | -18.4M | -68.6M | -75.7M | -80.8M | -36.1M | -17.8M | |
INVESTING ACTIVITIES | |||||||
-518K | -36K | -486K | -1.9M | -1.1M | -2.2M | -715K | |
-518K | -36K | -486K | -1.9M | -1.1M | -2.2M | -715K | |
FINANCING ACTIVITIES | |||||||
87.8M | 6.8M | 202K | 16K | 116.4M | 0.0 | 10M | |
0.0 | -3.4M | -6.8M | -85K | -110K | -99K | 10M | |
0.0 | 25.8M | 0.0 | 0.0 | -467K | 159K | -10M | |
87.8M | 29.2M | -6.6M | -69K | 260.7M | 10M | 60M | |
CASH FLOW SUMMARY | |||||||
0.0 | 0.0 | -25K | -9K | 0.0 | 0.0 | 0.0 | |
82.3M | 10.8M | -75.7M | -77.7M | 178.8M | -28.3M | 41.5M | |
57.1M | 46.3M | 120.4M | 198.1M | 20.8M | 49M | 7.6M | |
139.3M | 57.1M | 44.7M | 120.4M | 199.6M | 20.8M | 49M | |
-5.5M | -18.4M | -69.1M | -77.6M | -81.9M | -38.3M | -18.6M |
SEC Filings
XLO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
S-3/A S-3/A (Amended) N/A | May 27, 2026 | May 27, 2026 | ||
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
S-3 S-3 N/A | May 12, 2026 | May 12, 2026 | ||
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 10, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 16, 2026 | April 15, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 23, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 23, 2026 | March 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 12, 2026 | March 12, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 |
Related Guides
Continue your XLO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.